All cases included in this study were characterized for BRCA1/2 germline mutations, the major genetic risk factor for MBC, and for the main clinical-pathologic features including: family and personal history of cancer, ER, PR, HER2 and Ki67/MIB1 expression and tumor grade (G). Here, MIB1 is linked to neoplasm.